“In this relatively poor-risk cohort of older adults with newly diagnosed AML, decitabine for 5 and 10 days resulted in similar response rates, survival, and early mortality,” he concluded.
This study was funded by a University of Texas MD Anderson Cancer Center support grant. Dr. Short reported having no financial disclosures.
The Acute Leukemia Forum is held by Hemedicus, which is owned by the same company as this news organization.
SOURCE: Short NJ et al. ALF 2018, Poster Session.